Trials / Completed
CompletedNCT00806481
Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
Does Phosphate Binding With Sevelamer Carbonate Improve Cardiovascular Structure and Function in Patients With Early Chronic Kidney Disease?
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- University Hospital Birmingham NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevelamer carbonate | Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks |
| DRUG | Placebo | Treatment group: treatment with tablets of placebo three times daily for 36 weeks |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2008-12-10
- Last updated
- 2011-11-23
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00806481. Inclusion in this directory is not an endorsement.